

Rong Tian

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4881227/publications.pdf>

Version: 2024-02-01

42
papers

712
citations

567281

15
h-index

580821

25
g-index

44
all docs

44
docs citations

44
times ranked

905
citing authors

#	ARTICLE	IF	CITATIONS
1	Quantifying the contribution of 18F-FDG PET to the diagnostic assessment of pediatric patients with fever of unknown origin: a systematic review and meta-analysis. <i>Pediatric Radiology</i> , 2022, 52, 1500-1511.	2.0	5
2	Versatile polyphenolic platforms in regulating cell biology. <i>Chemical Society Reviews</i> , 2022, 51, 4175-4198.	38.1	76
3	More Evidence Is Warranted to Establish the Role of 18FDG-PET/CT in Fever of Unknown Origin (FUO) Investigations Among Children. <i>Clinical Infectious Diseases</i> , 2021, 73, e2842-e2844.	5.8	3
4	Use of radiomics based on 18F-FDG PET/CT and machine learning methods to aid clinical decision-making in the classification of solitary pulmonary lesions: an innovative approach. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2904-2913.	6.4	37
5	Clinical applications of single-photon emission computed tomography/computed tomography in post-ablation 131iodine scintigraphy in children and young adults with differentiated thyroid carcinoma. <i>Pediatric Radiology</i> , 2021, 51, 1724-1731.	2.0	8
6	The use of systematic review evidence to support the development of guidelines for positron emission tomography: a cross-sectional survey. <i>European Radiology</i> , 2021, 31, 6992-7002.	4.5	2
7	Assessment of the prognostic value of interim fluorodeoxyglucose positron emission tomography/computed tomography in nasal-type extranodal natural killer/T-cell lymphoma. <i>Quantitative Imaging in Medicine and Surgery</i> , 2021, 11, 1220-1233.	2.0	1
8	Prognostic value of lymph node ratio in children and adolescents with papillary thyroid cancer. <i>Clinical Endocrinology</i> , 2021, 95, 649-656.	2.4	8
9	Investigating 18F-FDG PET/CT Parameters as Prognostic Markers for Differentiated Thyroid Cancer: A Systematic Review. <i>Frontiers in Oncology</i> , 2021, 11, 648658.	2.8	15
10	Methodological quality of systematic reviews used in clinical practice guidelines: focus on clinical imaging. <i>Clinical and Translational Imaging</i> , 2021, 9, 373-382.	2.1	2
11	The Diagnostic Role of 18F-Choline, 18F-Fluciclovine and 18F-PSMA PET/CT in the Detection of Prostate Cancer With Biochemical Recurrence: A Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 684629.	2.8	37
12	Editorial: Novel Methods for Oncologic Imaging Analysis: Radiomics, Machine Learning, and Artificial Intelligence. <i>Frontiers in Oncology</i> , 2021, 11, 628310.	2.8	2
13	The effect of hypothyroidism on referential background metabolic activity on 18F-FDG PET/CT. <i>Quantitative Imaging in Medicine and Surgery</i> , 2021, 11, 3666-3676.	2.0	3
14	Inpatient repeatability of background 18F-FDG uptake on PET/CT. <i>Quantitative Imaging in Medicine and Surgery</i> , 2021, 11, 4172-4180.	2.0	3
15	18F-FDG PET/CT Imaging of Pancreatic and Adrenal Metastases in a Patient With Mesenchymal Chondrosarcoma. <i>Clinical Nuclear Medicine</i> , 2021, 46, 231-232.	1.3	3
16	Solitary Bone Langerhans Cell Histiocytosis Demonstrated on Multimodality Imaging in an Adult. <i>Clinical Nuclear Medicine</i> , 2020, 45, 78-80.	1.3	9
17	New Frontiers in Molecular Imaging Using Peptide-Based Radiopharmaceuticals for Prostate Cancer. <i>Frontiers in Chemistry</i> , 2020, 8, 583309.	3.6	13
18	Current status and quality of radiomics studies in lymphoma: a systematic review. <i>European Radiology</i> , 2020, 30, 6228-6240.	4.5	41

#	ARTICLE	IF	CITATIONS
19	68Ga-PSMA PET/MRI for the diagnosis of primary and biochemically recurrent prostate cancer: A meta-analysis. <i>European Journal of Radiology</i> , 2020, 130, 109131.	2.6	15
20	Development and validation of an 18F-FDG PET radiomic model for prognosis prediction in patients with nasal-type extranodal natural killer/T cell lymphoma. <i>European Radiology</i> , 2020, 30, 5578-5587.	4.5	27
21	Adrenal and Bone Metastases as the Initial Presentation of Endometrial Carcinoma Diagnosed by 18F-FDG PET/CT. <i>Clinical Nuclear Medicine</i> , 2020, 45, 711-713.	1.3	3
22	Prediction of Overall Survival and Progression-Free Survival by the ¹⁸ F-FDG PET/CT Radiomic Features in Patients with Primary Gastric Diffuse Large B-Cell Lymphoma. <i>Contrast Media and Molecular Imaging</i> , 2019, 2019, 1-9.	0.8	32
23	<p>Bombesin-functionalized superparamagnetic iron oxide nanoparticles for dual-modality MR/NIRFI in mouse models of breast cancer</p>. <i>International Journal of Nanomedicine</i> , 2019, Volume 14, 6721-6732.	6.7	17
24	PET/CT-based bone-marrow assessment shows potential in replacing routine bone-marrow biopsy in part of patients newly diagnosed with extranodal natural killer/T-cell lymphoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 2529-2539.	2.5	9
25	Positron Emission Tomography Imaging of Platelet-Derived Growth Factor Receptor $\hat{1}^2$ in Colorectal Tumor Xenograft Using Zirconium-89 Labeled Dimeric Affibody Molecule. <i>Molecular Pharmaceutics</i> , 2019, 16, 1950-1957.	4.6	16
26	Ability of ¹⁸ F-FDG PET/CT Radiomic Features to Distinguish Breast Carcinoma from Breast Lymphoma. <i>Contrast Media and Molecular Imaging</i> , 2019, 2019, 1-9.	0.8	33
27	Humeral metastasis of sacrococcygeal chordoma detected by fluorine-18 fluorodeoxyglucose positron emission tomography-computed tomography: A case report. <i>Radiology Case Reports</i> , 2018, 13, 449-452.	0.6	5
28	Uterine Corpus Metastasis From Rectal Adenocarcinoma Detected Using 18F-FDG PET/CT. <i>Clinical Nuclear Medicine</i> , 2018, 43, 614-616.	1.3	3
29	Bombesin functionalized ⁶⁴ Cu-copper sulfide nanoparticles for targeted imaging of orthotopic prostate cancer. <i>Nanomedicine</i> , 2018, 13, 1695-1705.	3.3	23
30	Prognostic value of baseline, interim and end-of-treatment 18F-FDG PET/CT parameters in extranodal natural killer/T-cell lymphoma: A meta-analysis. <i>PLoS ONE</i> , 2018, 13, e0194435.	2.5	22
31	Predictive approaches for post-therapy PET/CT in patients with extranodal natural killer/T-cell lymphoma. <i>Nuclear Medicine Communications</i> , 2017, 38, 937-947.	1.1	7
32	Targeted Imaging of Tumor-Associated Macrophages by Cyanine 7-Labeled Mannose in Xenograft Tumors. <i>Molecular Imaging</i> , 2017, 16, 153601211668949.	1.4	26
33	A phase II prospective study of the "Sandwich" protocol, L-asparaginase, cisplatin, dexamethasone and etoposide chemotherapy combined with concurrent radiation and cisplatin, in newly diagnosed, I/II stage, nasal type, extranodal natural killer/T-cell lymphoma. <i>Oncotarget</i> , 2017, 8, 50155-50163.	1.8	28
34	A phase II prospective clinical study of the "sandwich" protocol, VDLP combined with concurrent radiation and cisplatin in newly diagnosed, I/II stage, nasal type, extranodal natural killer/T-cell lymphoma.. <i>Journal of Clinical Oncology</i> , 2016, 34, 7553-7553.	1.6	0
35	The Limited & Extensive Staging System Is More Suitable for Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: Comparison with Other Staging Systems. <i>Blood</i> , 2016, 128, 4155-4155.	1.4	0
36	A pulmonary chondromatous hamartoma resembling multiple metastases in the (18)F-FDG PET/CT scan. <i>Hellenic Journal of Nuclear Medicine</i> , 2016, 19, 176-8.	0.3	4

#	ARTICLE	IF	CITATIONS
37	Primary glioblastoma of the cerebellar vermis: A case report. <i>Oncology Letters</i> , 2015, 10, 402-404.	1.8	4
38	The Deauville 5-Point Scale Improves the Prognostic Value of Interim FDG PET/CT in Extranodal Natural Killer/T-Cell Lymphoma. <i>Clinical Nuclear Medicine</i> , 2015, 40, 767-773.	1.3	25
39	Assessment of the prognostic capacity of pretreatment, interim, and post-therapy 18F-FDG PET/CT in extranodal natural killer/T-cell lymphoma, nasal type. <i>Annals of Nuclear Medicine</i> , 2015, 29, 442-451.	2.2	24
40	Radiation Safety Precautions in 131I Therapy of Graves' Disease Based on Actual Biokinetic Measurements. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 2934-2941.	3.6	9
41	Imaging Myocardial Ischemia and Reperfusion Injury via Cy5.5-Annexin V. <i>Nuclear Medicine and Molecular Imaging</i> , 2012, 46, 155-161.	1.0	4
42	Dual-time point PET/CT with F-18 FDG for the differentiation of malignant and benign bone lesions. <i>Skeletal Radiology</i> , 2009, 38, 451-458.	2.0	108